Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
NASDAQ:EDIT
Price:
5.67 USD
0.89%
Market Closed
Updated:
May 5, 2024
EV/S
Enterprise Value to Sales
Enterprise Value to Sales
1.8
Current
16.3
Median
7.5
Industry
Lower
than median
Lower
than industry value
Enterprise Value to Sales (EV/S) ratio is a valuation multiple that compares the enterprise value (EV) of a company to its revenues. The EV/S multiple gives investors a quantifiable metric of how to value a company based on its sales while taking account of both the company's equity and debt.
EV/S
=1.8
Enterprise Value
/
140.5m
Revenue
78.1m
All Countries
| Market Cap | EV/S | ||||
|---|---|---|---|---|---|
| US |
|
Editas Medicine Inc
NASDAQ:EDIT
|
463.6m USD | 1.8 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
289.2B USD | 6.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
166.7B USD | 7.8 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
104.7B USD | 6.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.4B USD | 9.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133.2B AUD | 6.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.7B USD | 2.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
47.8B USD | 5.8 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.2 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.7B USD | 3.8 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 18.4 |
EV/S Forward Multiples
Forward EV/S multiple is a version of the EV/S ratio that uses forecasted revenue for the EV/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/S
3.8
2-Years Forward
EV/S
4.8
3-Years Forward
EV/S
1.8
You don't have any saved screeners yet
